Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

Corbus Pharmaceuticals announced that CEO Yuval Cohen will present a corporate overview and participate in investor meetings at the RBC Capital Markets Global Healthcare Conference (May 19-20, 2026) and the Jefferies Global Healthcare Conference (June 2-4, 2026). The clinical-stage company is developing CRB-701, an antibody drug conjugate for Nectin-4-expressing tumors, and CRB-913, an obesity treatment candidate.

05/13/2026, 7:00 AM • GlobeNewswire

Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals announced FDA alignment on the registration path for CRB-701 in head and neck squamous cell carcinoma and cervical cancer, with a registrational study expected to launch this summer. The company completed enrollment in its CANYON-1 Phase 1b study of CRB-913 for obesity treatment with topline data expected summer 2026. Q1 2026 net loss was $23.0 million with $138.2 million in cash expected to fund operations into 2028.

05/12/2026, 8:00 AM • GlobeNewswire

Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference

Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage oncology and obesity company, announced that CEO Yuval Cohen will present a corporate overview and attend investor meetings at the 36th Annual Oppenheimer Healthcare Life Sciences Conference on February 25, 2026. The company's pipeline includes CRB-701 (antibody drug conjugate), CRB-601 (anti-integrin monoclonal antibody), and CRB-913 (CB1 inverse agonist for obesity treatment), which recently demonstrated a favorable safety profile and emerging evidence of weight loss in Phase 1a studies.

02/12/2026, 8:00 AM • GlobeNewswire

Corbus Pharmaceuticals Announces Pricing of Public Offering

Corbus Pharmaceuticals has priced a public offering of 4,744,231 common stock shares and pre-funded warrants, raising approximately $75 million to fund clinical development and corporate purposes.

10/31/2025, 2:40 AM • Benzinga

Corbus Pharmaceuticals Announces Pricing of Public Offering

Corbus Pharmaceuticals plans to raise approximately $75 million through a public offering of 4,744,231 common stock shares and pre-funded warrants, with proceeds intended to fund clinical development and working capital.

10/31/2025, 2:40 AM • GlobeNewswire

Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

Corbus Pharmaceuticals announced promising Phase 1/2 clinical trial results for CRB-701, an antibody-drug conjugate targeting Nectin-4, showing robust response rates across head and neck, cervical, and urothelial cancers with a favorable safety profile.

10/18/2025, 3:00 AM • GlobeNewswire

Cannabinoid Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

The cannabinoid agonist market is gaining momentum with expanding medical cannabis legalization and growing clinical validation for treating chronic pain, epilepsy, and inflammatory conditions. Over 20 pharmaceutical companies are actively developing cannabinoid agonist drugs with promising pipeline candidates.

07/10/2025, 1:00 PM • GlobeNewswire